Beta-blockers in children with duchenne cardiomyopathy

Reviews on Recent Clinical Trials

Volumn 9, Issue 2, 2014, Pages 76-81

  Matsumura, Tsuyoshi ^a  

^a TONEYAMA NATIONAL HOSPITAL   (Japan)

Author keywords

Beta blocker; Cardiomyopathy; Cardioprotection; Duchenne muscular dystrophy; Heart failure; Heart rate reduction

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CARDIOMYOPATHY; CARDIOPULMONARY FUNCTION; CARDIOVASCULAR MORTALITY; CHILD; CHILDHOOD DISEASE; DUCHENNE MUSCULAR DYSTROPHY; HEART FAILURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART RATE; HUMAN; ISCHEMIA; MYOCARDITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RESPIRATORY CARE; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; TACHYCARDIA; COMPLICATION;

ADRENERGIC BETA-ANTAGONISTS; CHILD; HEART FAILURE; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE;

EID: 84924369336     PISSN: 15748871     EISSN: 18761038     Source Type: Journal    
DOI: 10.2174/1574887109666140908123856     Document Type: Article

References (83)

1. [1] Ishikawa Y, Miura T, Ishikawa Y, et al. Duchenne muscular dys trophy: survival by cardio-respiratory interventions. Neuromuscul Disord 2011; 21: 47-51.
2. [2] Matsumura T, Saito T, Fujimura H, Shinno S, Sakoda S. A longitudinal cause-of-death analysis of patients with Duchenne muscular dystrophy. Rinsho Shinkeigaku 2011; 51: 743-50.In Japanese.
3. [3] Tamura T, Shibuya T, Iida M, Ishihara T, Fukunaga H, Kyo S. Clinical evaluation of captopril in chronic cardiac dysfunction in patients with Duchenne muscular dystrophy. Rinsho Iyaku 1996; 12: 3635-46. In Japanese.
4. [4] Ishikawa Y, Bach JR, Ishikawa Y, Minami R. A management trial for Duchenne cardiomyopathy. Am J Phys Med Rehabil 1995; 74: 345-50.
5. [5] Ishikawa Y, Bach JR, Minami R. Cardioprotection for Duchenne's muscular dystrophy. Am Heart J 1999; 137: 895-902.
6. [6] Kajimoto H, Ishigaki K, Okumura K, et al. Beta-blocker therapy for cardiac dysfunction in patients with muscular dystrophy. Circ J 2006; 70: 991-4.
7. [7] Ogata H, Ishikawa Y, Ishikawa Y, Minami R. Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy. J Cardiol 2009; 53: 72-8.
8. [8] Matsumura T, Tamura T, Kuru S, Kikuchi Y, Kawai M. Carvedilol can prevent cardiac events in Duchenne muscular dystrophy. Intern Med 2010; 49: 1357-63.
9. [9] Fayssoil A. Angiotensin-converting enzyme inhibitors and beta-blockers in cardiac asymptomatic patients with Duchenne muscular dystrophy. Indian Heart J 2010; 62: 273-273.
10. [10] Viollet L, Thrush PT, Flanigan KM, Mendell JR, Allen HD. Effects of angiotensin-converting enzyme inhibitors and/or beta blockers on the cardiomyopathy in Duchenne muscular dystrophy. Am J Cardiol 2012; 110: 98-102.
11. [11] Kwon HW, Kwon BS, Kim GB, et al. The effect of enalapril and carvedilol on left ventricular dysfunction in middle childhood and adolescent patients with muscular dystrophy. Korean Circ J 2012; 42: 184-91.
12. [12] Frankel KA, Rosser RJ. The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis. Hum Pathol 1976; 7: 375-86.
13. [13] Sanyal SK, Johnson WW. Cardiac conduction abnormalities in children with Duchenne's progressive muscular dystrophy: electro-cardiographic features and morphologic correlates. Circulation 1982; 66: 853-63.
14. [14] Moriuchi T, Kagawa N, Mukoyama M, Hizawa K. Autopsy analyses of the muscular dystrophies. Tokushima J Exp Med 1993; 40: 83-93.
15. [15] Hor KN, Mazur W, Taylor MD, et al. Effects of steroids and angio-tensin converting enzyme inhibition on circumferential strain in boys with Duchenne muscular dystrophy: a cross-sectional and longitudinal study utilizing cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2011; 13: 60.
16. [16] Barber BJ, Andrews JG, Lu Z, et al. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy. J Pediatr 2013; 163: 1080-4. e1.
17. [17] American Academy of Pediatrics Section on Cardiology and Cardiac Surgery. Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy. Pediatrics 2005; 116: 1569-73.
18. [18] Bushby K, Finkel R, Birnkrant DJ, et al. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. Lancet Neurol 2010; 9: 177-89.
19. [19] Schmidt GN, Burmeister MA, Lilje C, Wappler F, Bischoff P. Acute heart failure during spinal surgery in a boy with Duchenne muscular dystrophy. Br J Anaesth 2003; 90: 800-4.
20. [20] Slucka C. The electrocardiogram in Duchenne progressive muscular dystrophy. Circulation 1968; 38: 933-40.
21. [21] Nigro G, Comi LI, Politano L, Bain RJ. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. Int J Cardiol 1990; 26: 271-7.
22. [22] James J, Kinnett K, Wang Y, Ittenbach RF, Benson DW, Cripe L. Electrocardiographic abnormalities in very young Duchenne muscular dystrophy patients precede the onset of cardiac dysfunction. Neuromusc Disord 2011; 21: 462-7.
23. [23] Thrush PT, Allen HD, Viollet L, Mendell JR. Re-examination of the electrocardiogram in boys with Duchenne muscular dystrophy and correlation with its dilated cardiomyopathy. Am J Cardiol 2009; 103: 262-5.
24. [24] Thrush PT, Edward N, Flanigan KM, Mendell JR, Allen HD. Pre-cordial R wave height does not correlate with echocardiographic findings in boys with Duchenne muscular dystrophy. Congenit Heart Dis 2013; 8: 561-7.
25. [25] Kirchmann CL, Kececioglu D, Korinthenberg R, Dittrich S. Echo-cardiographic and electrocardiographic findings of cardiomyopathy in Duchenne and Becker-Kiener muscular dystrophies. Pediatr Cardiol 2005; 26: 66-72.
26. [26] Fayssoil A, Orlikowski D, Nardi O, Annane D. Complete atrioven-tricular block in Duchenne muscular dystrophy. Europace 2008; 10: 1351-2.
27. [27] Kuru S, Tanahashi T, Matsumoto S, Kitamura T, Konagaya M. Complete atrioventricular block in Duchenne muscular dystrophy. Rinsho Shinkeigaku 2012; 52: 685-7. In Japanese.
28. [28] Chenard AA, Becane HM, Tertrain F, de Kermadec JM, Weiss YA. Ventricular arrhythmia in Duchenne muscular dystrophy: prevalence, significance and prognosis. Neuromuscul Disord 1993; 3: 201-6.
29. [29] Heymsfield SB, McNish T, Perkins J V, Felner JM. Sequence of cardiac changes in Duchenne muscular dystrophy. Am Heart J 1978; 95: 283-94.
30. [30] Bahler RC, Mohyuddin T, Finkelhor RS, Jacobs IB. Contribution of Doppler tissue imaging and myocardial performance index to assessment of left ventricular function in patients with Duchenne's muscular dystrophy. J Am Soc Echocardiogr 2005; 18: 666-73.
31. [31] Giatrakos N, Kinali M, Stephens D, Dawson D, Muntoni F, Nihoy-annopoulos P. Cardiac tissue velocities and strain rate in the early detection of myocardial dysfunction of asymptomatic boys with Duchenne's muscular dystrophy: relationship to clinical outcome. Heart 2006; 92: 840-2.
32. [32] Mori K, Hayabuchi Y, Inoue M, et al. Myocardial strain imaging for early detection of cardiac involvement in patients with Duchenne's progressive muscular dystrophy. Echocardiography 2007; 24: 598-608.
33. [33] Ogata H, Nakatani S, Ishikawa Y, et al. Myocardial strain changes in Duchenne muscular dystrophy without overt cardiomyopathy. Int J Cardiol 2007; 115: 190-5.
34. [34] Saito Y, Komiya T, Kawai M. Hypercoagulable state in Duchenne muscular dystrophy. Rinsho Shinkeigaku 1997; 37: 374-8.In Japanese.
35. [35] Nakayama T, Saito Y, Uchiyama T, Yatabe K, Kawai M. Patho-genesis of pulmonary thrombosis in Duchenne muscular dystrophy: a consideration from changes in serum CK and LDH levels. Rinsho Shinkeigaku 2000; 40: 55-8. In Japanese.
36. [36] Saito T, Yamamoto Y, Matsumura T, Nozaki S, Fujimura H, Shinno S. Coagulation system activated in Duchenne muscular dystrophy patients with cardiac dysfunction. Brain Dev 2005; 27: 415-8.
37. [37] Gimenez-Muñoz A, Capablo JL, Alarcia R, Torné L, Errea JM. Intracardiac thrombus and cerebral infarction in a patient with duchenne muscular dystrophy. J Clin Neuromuscul Dis 2009; 11: 79-80.
38. [38] Tsakadze N, Katzin LW, Krishnan S, Behrouz R. Cerebral infarction in Duchenne muscular dystrophy. J Stroke Cerebrovasc Dis 2011; 20: 264-5.
39. [39] Varghese A, Pennell DJ. Late gadolinium enhanced cardiovascular magnetic resonance in Becker muscular dystrophy. Heart 2004; 90: e59-e59.
40. [40] Silva MC, Meira ZM, Gurgel Giannetti J, et al. Myocardial delayed enhancement by magnetic resonance imaging in patients with muscular dystrophy. J Am Coll Cardiol 2007; 49: 1874-9
41. [41] Mavrogeni S, Papavasiliou A, Spargias K, et al. Myocardial inflammation in Duchenne muscular dystrophy as a precipitating factor for heart failure: a prospective study. BMC Neurol 2010; 10: 33.
42. [42] Walcher T, Steinbach P, Spiess J, et al. Detection of long-term progression of myocardial fibrosis in Duchenne muscular dystrophy in an affected family: a cardiovascular magnetic resonance study. Eur J Radiol 2011; 80: 115-9.
43. [43] Menon SC, Etheridge SP, Liesemer KN, et al. Predictive value of myocardial delayed enhancement in Duchenne muscular dystrophy. Ped Cardiol 2014; 35(7): 1279-85.
44. [44] Ashford MW Jr, Liu W, Lin SJ, et al. Occult cardiac contractile dysfunction in dystrophin-deficient children revealed by cardiac magnetic resonance strain imaging. Circulation 2005; 112: 2462-7.
45. [45] Hor KN, Wansapura J, Markham LW, et al. Circumferential strain analysis identifies strata of cardiomyopathy in Duchenne muscular dystrophy: a cardiac magnetic resonance tagging study. J Am Coll Cardiol 2009; 53: 1204-10.
46. [46] Hagenbuch SC, Gottliebson WM, Wansapura J, et al. Detection of progressive cardiac dysfunction by serial evaluation of circumferential strain in patients with Duchenne muscular dystrophy. Am J Cardiol 2010; 105: 1451-5.
47. [47] Nishimura T, Yanagisawa A, Sakata H, et al. Thallium-201 single photon emission computed tomography (SPECT) in patients with Duchenne's progressive muscular dystrophy: a histopathologic correlation study. Jpn Circ J 2001; 65: 99-105.
48. [48] Stewart CA, Gilgoff I, Baydur A, Prentice W, Applebaum D. Gated radionuclide ventriculography in the evaluation of cardiac function in Duchenne's muscular dystrophy. Chest 1988; 94: 1245-8.
49. [49] Fu P, Hu L, Sinzinger J, Huang J, Liu X. Assessment of cardiac abnormalities in Duchenne's muscular dystrophy by (99m)Tc-MIBI gated myocardial perfusion imaging. Hell J Nucl Med 2012; 15: 114-9.
50. [50] Kaminaga T, Matsumura K, Hatanaka H, Shimizu T. Abnormality of the myocardial sympathetic nervous system in a patient with Becker muscular dystrophy detected with iodine-123 metaiodoben-zylguanidine scintigraphy. Clin Nucl Med 2001; 26: 701-3.
51. [51] Mori K, Manabe T, Nii M, Hayabuchi Y, Kuroda Y, Tatara K. Plasma levels of natriuretic peptide and echocardiographic parameters in patients with Duchenne's progressive muscular dystrophy. Pediatr Cardiol 2002; 23: 160-6.
52. [52] Demachi J, Kagaya Y, Watanabe J, et al. Characteristics of the increase in plasma brain natriuretic peptide level in left ventricular systolic dysfunction, associated with muscular dystrophy in comparison with idiopathic dilated cardiomyopathy. Neuromuscul Dis-ord 2004; 14: 732-9.
53. [53] Matsumura T, Saito T, Fujimura H, Shinno S. Cardiac troponin I for accurate evaluation of cardiac status in myopathic patients. Brain Dev 2007; 29: 496-501.
54. [54] Matsumura T, Yoshio T, Yamamoto K, Saito T, Fujimura H, Shinno S. Anti-beta 1 adrenoreceptor antibody is frequently elevated in patients with muscular dystrophy. Rinsho Shinkeigaku 2006; 46: 687-92. In Japanese.
55. [55] Matsumura T, Saito T, Fujimura H, Sakoda S. Renal dysfunction is a frequent complication in patients with advanced stage of Duchenne muscular dystrophy. Rinsho Shinkeigaku 2012; 52: 211-7. In Japanese.
56. [56] Wu RS, Gupta S, Brown RN, et al. Clinical outcomes after cardiac transplantation in muscular dystrophy patients. J Heart Lung Transplant 2010; 29: 432-8.
57. [57] Amodeo A, Adorisio R. Left ventricular assist device in Duchenne cardiomyopathy: can we change the natural history of cardiac disease? Int J Cardiol 2012; 161: e43.
58. [58] Saito T, Shinno S. How we have treated and cared for patients with Duchenne muscular dystrophy and severe congestive heart failure. No To Hattatsu 2005; 37: 281-6. In Japanese.
59. [59] Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med 1991; 325: 293-302.
60. [60] Kjekshus J, Swedberg K, Snapinn S. Effects of enalapril on long-term mortality in severe congestive heart failure. CONSENSUS Trial Group. Am J Cardiol 1992; 69: 103-7.
61. [61] Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997; 349: 747-52.
62. [62] Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial--the Losartan Heart Failure Survival Study ELITE II. Lancet 2000; 355: 1582-7.
63. [63] Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-75.
64. [64] Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759-66.
65. [65] Waagstein F, Bristow MR, Swedberg K. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. Lancet 1993; 342: 1441-6.
66. [66] Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334: 1349-55.
67. [67] Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators. Circulation 1996; 94: 2807-16
68. [68] Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-7.
69. [69] The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9-13.
70. [70] Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-8.
71. [71] Remme WJ; CARMEN Steering Committee and Investigators. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure EvaluatioN trial (CARMEN)--rationale and design. Cardiovasc Drugs Ther 2001; 15: 69-77.
72. [72] Hori M, Sasayama S, Kitabatake A, et al. Low-dose carvedilol improves left ventricular function and reduces cardiovascular hos-pitalization in Japanese patients with chronic heart failure: the Mul-ticenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial. Am Heart J 2004; 147: 324-30.
73. [73] Okamoto H, Hori M, Matsuzaki M, et al. Minimal dose for effective clinical outcome and predictive factors for responsiveness to carvedilol: Japanese chronic heart failure (J-CHF) study. Int J Car-diol 2013; 164: 238-44.
74. [74] Spurney CF. Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions. Muscle Nerve 2011; 44: 8-19.
75. [75] Duboc D, Meune C, Pierre B, et al. Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J 2007; 154: 596-602.
76. [76] Saito T, Matsumura T, Miyai I, Nozaki S, Shinno S. Carvedilol effectiveness for left ventricular-insufficient patients with Duchenne muscular dystrophy. Rinsho Shinkeigaku 2001; 41: 691-4. In Japanese.
77. [77] Nakata T, Wakabayashi T, Kyuma M, Takahashi T, Tsuchihashi K, Shimamoto K. Cardiac metaiodobenzylguanidine activity can predict the long-term efficacy of angiotensin-converting enzyme inhibitors and/or beta-adrenoceptor blockers in patients with heart failure. Eur J Nucl Med Mol Imaging 2005; 32: 186-94.
78. [78] Fujimoto S, Inoue A, Hisatake S, et al. Usefulness of meta-[123I] iodobenzylguanidine myocardial scintigraphy for predicting cardiac events in patients with dilated cardiomyopathy who receive long-term beta blocker treatment. Nucl Med Commun 2005; 26: 97-102.
79. [79] Kasama S, Toyama T, Hatori T, et al. Evaluation of cardiac sympathetic nerve activity and left ventricular remodelling in patients with dilated cardiomyopathy on the treatment containing carve-dilol. Eur Heart J 2007; 28: 989-95.
80. [80] McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong P W. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784-94.
81. [81] Kjekshus J. Is there a heart rate paradox--demystification of the myths? J Intern Med 2009; 266: 242-7.
82. [82] Jia H, Hingorani AD, Sharma P, et al. Association of the G(s) alpha gene with essential hypertension and response to beta-blockade. Hypertension 1999; 34: 8-14.
83. [83] Johnson JA, Zineh I, Puckett BJ, McGorray S P, Yarandi HN, Pauly D F. Beta 1-adrenergic receptor polymorphisms and antihyperten-sive response to metoprolol. Clin Pharmacol Ther 2003; 74: 44-52.